PATENT CLAIM ANALYSIS

Application Number: 15996612
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-09
Patent Classification: ["530", "331000"]

Abstract:
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Claim (Index 40):
The conjugate of  claim 30  wherein L comprises a chain of at least about 16 atoms.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 94.0
- Lexical Diversity: 1.72727
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14443212', '15245505', '15997451', '15990111', '15990136']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6135207544273984
- 35 USC 102 Novelty (BERT): 0.5455721950109232
- Combined Prediction Score: 0.6067258984857509
- Mean Citation Score: 322.859174
- Max Citation Score: 395.9328
- Similarity Product: 227.09874477596284

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test